Moderna is fighting a shareholder proposal demanding the pharma group open up its Covid-19 vaccine technology to poorer countries and explain why its prices are so high given the amount of government assistance it has received.
Legal & General Investment Management, the London-based asset manager, said Moderna’s shareholders deserve to know how US government funding for Covid vaccines affects “access to such products, such as setting prices”.
Having received at least $2.5bn from the US government, Moderna has shipped vaccines to mostly wealthy countries and has not transferred its technology to manufacturers in low- or middle-income countries, LGIM said.
您已閱讀24%（660字），剩余76%（2061字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。